Why Is CARIS LIFE SCIENCES (CAI) Stock Up Today?

Caris Life Sciences shares rose 5.62% to $31.19 on Tuesday, driven by a wave of positive analyst revisions and new scientific data. The move reflects heightened confidence in the company’s artificial intelligence and precision medicine platforms following recent study presentations and expanded partnerships.

What Happened

Two major investment banks raised their price targets for the stock within the last 36 hours. JPMorgan increased its target to $35 from $25, while TD Cowen lifted its target to $36 from $30. Both firms maintained positive ratings on the shares. The company also announced it will present eight studies at the ESMO 2026 conference, highlighting AI-driven approaches to treatment prediction, risk stratification, and biomarker discovery across multiple cancer types. Additionally, CAI expanded its partnership in Delaware to meet new benefit accuracy requirements, a move that underscores its growing role in the healthcare benefits ecosystem.

What The Data Shows

The stock printed 16 fresh 52-week highs on October 14, 2026, capping a strong upward trend. Fundamentals show a market capitalization of $8.4 billion with a trailing twelve-month revenue growth of 85.4% and a net margin of 10.6%. The current price-to-earnings ratio stands at 79.6. Intraday, the stock opened at $29.65 and reached a session high of $31.45 at 10:00 AM ET. Volume was light at 0.6 million shares, which is 0.1 times the three-month daily average. Recent insider activity shows three sales totaling $27.2 million over the last 90 days, with no buys recorded. The most recent sale was filed on September 23, 2026.

What To Watch

Investors will monitor the upcoming presentation of the eight studies at ESMO 2026 for further validation of the company’s AI models. Continued analyst coverage and potential further price target adjustments will also be key factors in the near term.